London South East | The UK's favourite investor portal.

Major new fuel source ‘shows great potential’ as alternative to petrol and diesel (msn.com)

A new fuel source could be used in vehicles in the future with experts calling for more research and development to be done.

Ammonia is a zero-carbon fuel and has been touted by some as being a suitable and sustainable alternative fuel for the future of transport.

Soup I have previously admired some of your previous posts but unfortunately you have gone down in my estimation and do not take any pleasure in saying that. I have no problem with anyone criticising my posts if it can be justified, as no one is infallible. However, I feel you are spending to much time trying to impress on this BB and I hate to say it but you may have lost the plot or are trying to play games or you just need to go to spec savers. You appear to be taking things I have posted too personally, which has never been my intention.

I take no satisfaction in highlighting discrepancies made by a fellow poster, but I would suggest you proofread what you write, as your post Today 17:31 is pure nonsense. ‘Unfortunately I fear you may have not understood that Canadian government documents use the format YYYY-MM-DD, whereas your post (6 jul 22:33) works on the YYYY-DD-MM, therefore your timings are essentially wrong.’

Ref: see national Standards Council of Canada for confirmation.
https://www.scc.ca/en/standardsdb/standards/4449

This would mean that the first patent #1 (CA 2846460) was issued prior to any deal with Ebers. So is not relevant as you thought as it is dated January, not September.

I often refer to myself as a ‘Simple Yorkshire Lad’ but that cannot be further from the truth, so please don’t try to take the p**s. I have forgotten more about pharmaceutical research than you will ever know and would advise you to read my post again. Yes if I ever quote dates etc I always transpose these into my native timeline and that of the audience who will be reading it. The following is my exact transcript (you quote), which is completely different from what you are trying to insinuate: -

‘This #1 Patent for Ebers was granted patent status and issued on 01/08/2019 although we were not notified of it until 9th September 2019 RNS Number 6247L.’

Please feel free to check all my posts as then I will not have to worry about grammatical/spelling irregularities. I have not taken my bat and ball home and will continue to post information relevant to my investments as I think fit. Although, I will not be concerned whether you read them or not, however, if you post anything relevant, I will applaud you for sharing it. Good luck, stay well and let us please support NFX in achieving their objectives, not in ‘tit for tat’ correspondence. YB

Soup my apologies for not being able to reply earlier, but sometimes business dictates how much time we can give to other life areas. I hope you are well and enjoying the NFX ride, it reminds me a bit of the ‘Big Dipper’ at Blackpool pleasure beach with its ups/downs and the occasional settled moments. Personally, I’m enjoying the experience although I appreciate that for some it can be fraught at times. I will try and ensure that this post doesn’t turn into one of the ‘Bronte’ (by the way riosurfer an excellent post} novels, but unfortunately, I can’t promise.

Unfortunately, I find myself a little discombobulated by your post on 06 July 2020 23:01 as I did not realise that we ‘are in disagreement’! However, it would be of great help to myself and I’m sure others if you can please clarify/expand on your statement ‘Two points, look up what ‘Aprepitant’ is and you’ll find it’s relating to NXP001 and nothing to do with Ebers.’

Therefore, I would like to ask a genuine question. I agree it is very much associated with NXP001, especially within the growing oncology supportive care market. Does that mean it is restricted to this specialist market? If so, I sincerely apologise as it means I have completely misunderstood, because under the English Abstract and Claims section it states: -
’The 1:1:1 aprepitant L-proline H20 composition or cocrystal may be used in the same way as aprepitant to treat or prevent disorders relating to emesis, a neuropsychiatric disease, an inflammatory disease, pairs, cancer, a skin disease, itch, a respiratory disease, or an addiction.’

You may also be correct that it is ‘nothing to do with Ebers’? However, my assumption/hypothesis has been that news released by NFX means that certain patent milestones have been achieved and the timeline fits this, with the patent ownership remaining with the current owners Nuformix. I am sure we both try to post informative and evidence-based facts which may be beneficial for investors. Therefore, I have no problem if you disprove my hypothesis if investors receive the appropriate information.

Good luck and keep well.
YB

Following the publication of the review launched in 2018, entitled "First Do No Harm" is long overdue and I hope the people (mainly woman) who have suffered (potentially of malpractice) at least receive some redress that they deserve. Although I would imagine that nothing would compensate for the years of crippling, life-changing complications including chronic pain, infections, and loss of sex life. Listening to some of the interviews today, some expressed the desire that hopefully others would not have to endure what they had gone through.

I and others posted about this very issue on the 21st January 2020 ‘The future potential of dcell Technology is vast’:- (There are several links (although may now be slightly dated) incorporated into the post which may be useful as an ‘aide de memoire’ for long term holders and advantageous to new investors. Who could be selling their share at what some may feel is an undervalued price? I have included the first couple of initial paragraphs of the post below, although the full text etc, can be found on my posting history)

‘As shown by the excellent video posted by Boom123 today, there are significant issues associated with Urogynaecology mesh which is used to treat stress incontinence and pelvic organ prolapse. The very same product used in vaginal mesh surgery currently facing a number of lawsuits worldwide has been, and is currently being used, in hernia operations.
https://www.nhsnegligence.co.uk/hip-knee-spine-implants/hernia-mesh-implants/

As highlighted by the video a safe, effective, and endorsed alternative is urgently required and that is already available as most investors in TRX and the medical profession are becoming more and more aware. I.e.: - dCELL® technology A Decellularised Dermal Allograft is used to Manage a Patient's Soft Tissue Defects. Intended to be used to provide reinforcement, repair, or replacement of damaged or inadequate integumental tissue or for other homologous uses of human integument. female pelvic medicine & reconstructive surgery.’

Then following some excellent contributions by fellow posters on 21st February 2020 I posted, ‘RE: Publicity and opportunities for TRX?’

Large Number of women with transvaginal mesh require surgeries years later. (February 19th, 2020)
'An alarmingly high percentage of women who received transvaginal mesh implants to treat pelvic organ prolapse (POP) require additional surgeries years after being implanted with the devices, suggesting that problems with the devices won’t end anytime soon despite the removal of mesh for POP from the market last year.’
https://www.beasleyallen.com/news/large-number-of-women-with-transvaginal-mesh-require-surgeries-years-later/
’Empowering Surgeons’ which includes some excellent testimonials.’
https://www.armsmedical.com/surgeons/

To be continued

Hi Soup, many thanks for your comments and hopefully the following will clarify any issues. The following link identifies that so far there has been 3 specific Patent submissions to the Canadian Intellectual Property Office (CIPO). We must also keep in mind that they may have been filed at an earlier date with other organisations i.e. World Intellectual Property Office (WIPO) etc who may have been one of the first points of contact re Intellectual Property. Hopefully, this should address your query posted at 16:42?

Soup you will probably be aware of the following, so I do apologise. However, I’m sure there will be others who may benefit by the structured information. As unfortunately it can be a little confusing as I initially found out: -
https://www.ic.gc.ca/opic-cipo/cpd/eng/search/results.html?query=Nuformix

On this page you will note that in the left-hand First column each one is identified by the # Number in descending order (1, 2 & 3) followed by Second column # Patent (which is the Patent identification number) in descending order relating to the # number, and the Third is the Patent Title in descending order, obviously relating to both # number and # Patent

Therefore, the First #1 = # Patent CA 2846460 = APREPITANT L-PROLINE COMPOSITION AND COCRYSTAL’.
Click on the # Patent number and it takes you to the Patent information page. This provides a basic summary of the submission data, usually starting with the Bibliographic Data, if you ‘hover’ over the left-hand column headings, it gives you a brief description as to what it relates too. If you want additional information, (especially the science etc) click on the required boxes (white on a black background) Bibliographic Data, Abstracts, Claims etc, etc which are in row across the page.
https://www.ic.gc.ca/opic-cipo/cpd/eng/patent/2846460/summary.html?query=Nuformix&type=
This #1 Patent for Ebers was granted patent status and issued on 01/08/2019 although we were not notified of it until 9th September 2019 RNS Number 6247L.
The second is #2 = Patent CA 2892832 = APREPITANT L-PROLINE SOLVATES - COMPOSITIONS AND COCRYSTALS’. Click on the # Patent number and it takes you to the specific Patent information page
https://www.ic.gc.ca/opic-cipo/cpd/eng/patent/2892832/summary.html?query=Nuformix&type=
This #2 is the second Patent for Ebers and was initially filed with WIPO on 21/11/2012 and then granted patent status and issued by the CIPO on 14/04/2020 although we were not notified of it until 27th May 2020 RNS Number: 0476O.

The third of the three is #3 = Patent CA 2908440 = TRANILAST COMPOSITIONS AND COCRYSTALS. Click on the # Patent number and it takes you to the specific Patent information page
https://www.ic.gc.ca/opic-cipo/cpd/eng/patent/2908440/summary.html?query=Nuformix&type=
Continued

Continued: - Now to one area of mystery for some posters i.e. the collaboration with ‘VistaGen Therapeutics’. One poster said, ‘Vistagen sound like another useless lifestyle pharma that have ripped off their shareholders. They can't provide value to their own shareholders - I doubt a collaboration with make us rich.’ How has he come to that conclusion! Is it his/her own view (which he is totally entitled to), but it would be nice if they would justify their statement, perhaps they haven’t done their research in relation to: - VistaGen and Nuformix entering a strategic agreement to develop novel crystalline forms of AV-101 that may have superior delivery, an enhanced therapeutic profile and additional intellectual property protection. VistaGen Therapeutics maybe a small/medium pharma company who may not make us rich but, can be extremely beneficial in specialist unmet need areas. VistaGen is developing three differentiated, patent-protected, CNS product candidates for large global markets where current treatments are inadequate to address rising mental health challenges worldwide, as well as need for non-additive, non-sedating relief from pain, unwanted movement disorders and other neurological conditions besetting increasing numbers of individuals worldwide. VistaGen and Nuformix entered strategic agreement to develop novel crystalline forms of AV-101 that may have superior delivery, an enhanced therapeutic profile and additional intellectual property protection. USPTO issued Notice of Allowance for U.S. Patent Application 16/003,816 related to therapeutic use of AV-101 for treatment of dyskinesia induced by the administration of levodopa. Patent, once issued, will be in effect until at least 2034. FDA authorised Investigational New Drug (IND) application for AV-101 as a potential new treatment of dyskinesia in individuals with PD receiving levodopa therapy The FDA has authorised Investigational New Drug (IND) application for AV-101 as a potential new treatment of dyskinesia in individuals with PD receiving levodopa therapy.
https://seekingalpha.com/pr/17915692-vistagen-therapeutics-reports-fiscal-year-2020-results-and-provides-cns-pipeline-update
https://www.prnewswire.com/news-releases/vistagen-therapeutics-reports-fiscal-year-2020-results-and-provides-cns-pipeline-update-301085372.html
Does Vistagen have sufficient financial resources to positively support a collaboration/development. Hopefully, as in June 2020, the Company announced a strategic licensing deal with EverInsight for PH94B for anxiety disorders in multiple key Asian markets; VistaGen is eligible to receive up to $177M in upfront and milestone payments, in addition to royalties, including a $5M upfront payment.
https://seekingalpha.com/news/3587153-vistagen-therapeutics-reports-fy-results
I look forward to my 5* Round the World Cruise and living extremely contentedly (from my NFX profits) when I retire next year. Be patient and stay well. YB

It took centuries to dispel this myth, although, it would appear several posters on this BB may still believe it is. They may even believe that the earth is still flat and are afraid of venturing far in case they fall over the edge, despite all evidence to the contrary. Therefore, if you are going to post disparaging, disingenuous and potentially libellous comments, I would politely suggest that you at least evidence, your spurious and obfuscating comments.

Life and Business is influenced by many factors and sometimes do not always run smoothly or how we want it to. Unfortunately, at the moment this appears to be happening with NFX and they are dammed if they do and dammed if they do not. News will come at the appropriate time, although it would appear not quick enough for some who probably haven’t got the faintest idea about business acumen, especially when it comes to research development, due diligence, sensitive negotiations and timelines. Although, do they really need to know when every i has been dotted and every t has been crossed. I suppose they would say yes, as they would argue that they’ve got a couple of quid invested and need the 10% profit to go to ‘Blackpool’ (no disrespect to Blackpool as I actually love it) but other resorts are available.

Do they not also realise that there are very astute, knowledgeable, and researched contributors, who give their time and effort to enable us to make informed decisions about our investment strategy. and the disservice they give to these posters. As a Yorkshire Lad from Gods own country I can be a little forthright (although our lass says I think I am never wrong lol), I do try to base my contributions on researched evidence. Therefore, for those who read my posts titled ‘Developments are Developing’ they are aware that business/developments/progress have not ground to a halt, especially regarding Ebers. As we know a second patent (Patent CA 2892832) was granted and issued on 14/04/2020 and therefore achieved another milestone payment. Although, it was after the 2019/2020 financial year end, so may be referred to, but not included in the year end accounts. The next maintenance payment for this is due 23/11/2020.
https://www.ic.gc.ca/opic-ipo/cpd/eng/patent/2892832/summary.html?query=Nuformix+&type=basic_search

In GreggsStottie post (04 Jul 2020 23:03) he highlights: - ‘I recall speaking to Dan in May and he said there had been some delays to one of the EBERS patent applications as a result of a change to the application....they had improved the cocrystal and the amend meant a delay. The payment was due at the end of May I think.’
Greggs is quite right, although this is for the 3rd patent application (Patent CA 2908440) which is for Tranilist Compositions. The ‘Amendments & Claims’’ were submitted on 09/04/2020 and I believe we are still awaiting the final (the wheels of bureaucracy can grind very slowly) outcome.
https://www.ic.gc.ca/opic-cipo/cpd/eng/patent/2908440/summa

Thankfully, there are astute, intelligent, and extremely knowledgeable posters on this BB. Who mercifully do not get sucked into the ‘Herd/mob/pack mentality’? This means they are not influenced by their peers to adopt certain thinking/behaviours on a largely emotional, rather than rational basis. Throughout my posts I have always tried to maintain that posters should be entitled to their own views and personally try not to be critical of these or engage in debate, despite how unscrupulous they may appear to be. Though, recently I have noticed that some posts (without justification/evidence as to their validity) could be interpreted as verging on being dishonest or even immoral, I believe with the intention to influence others to get what they want.

I acknowledge that company communication has been sparse but if you do your research, as many on this BB do. You will realise that business is progressing and I agree with GreggsStottie (sorry to hear you’ve cashed out of TRX, but hey ho!) re: hey ho Fri 18:12hrs ‘We should hear about the ebers payment in the next 2 weeks, then onwards and upwards to the Kissei deal in June July hopefully.... ‘
For those who fully assimilated my post: re: Developments are Developing. 11th May 2020 12:01, (especially 2nd (of 3)) they will probably have put 2 and 2 together and got 4, realising that Dan & Co have achieved another milestone, as required by the: - ‘Ebers’ agreement (RNS Tue, 9th Apr 2019 07:00 No 5048V, Nuformix PLC – Strategic Cannabinoid Agreement): – ‘today announces it has signed an agreement for cannabinoid therapeutics development, licensing and commercialisation containing up to £51 million of upfront, R&D and milestone payments, plus long-term royalties of 20% of net sales (the "Agreement").’
‘Under the terms of the Agreement and the expected development timeline, Nuformix will receive a significant upfront payment and believes it will earn further R&D and early-stage milestone payments up to a total of £1m during 2019. Further pre-clinical and clinical milestone payments are expected in 2020 and 2021, in addition to royalty payments of 20%, given the speed to market for consumer therapeutic products.’

This was further re-enforced in: - (RNS 9th Sept 2019- No 6247L) Ebers Cannabinoid Collaboration Update:
The number of patents filed is one of several key performance indicators for the collaboration and demonstrates the partnership and overall concept are well-founded. For Nuformix, this first patent filing creates a path to further income from Ebers. We will continue to inform the market as further patents are filed and milestones and royalties are paid in-line with the agreement". ‘The patented cannabinoid forms have immediate applications in both pharmaceutical and consumer products worldwide, which in due course, will generate further milestone payments, plus royalties to Nuformix of 20% under the Agreement terms.’

To be continued

In my opinion NO and I am sure there are numerous posters in agreement. This is evidenced by the excellent, detailed, intelligent, and insightful contributions to the discussions this morning and to those please accept my sincere thanks. This means I do not have to post repetitive information/views (like several posters) to justify my NO decision. Although, it would appear that a number of posters are still believing the miss information/representation provided by unscrupulous press outlets and de-rampers.

However, one news post did catch my eye, and I am unsure whether, it has been commented on. This was towards the end of the news item: - ‘Exclusive: First coronavirus antibody test given approval by Public Health England’ The Telegraph.
‘It emerged on Wednesday that the pharmacist Boots is advertising for an army of hundreds of unpaid volunteers to test people for coronavirus. An advertisement on the company's website said it is looking for 1,000 current staff and volunteers to work at least 32 hours a week as swab testers across the UK’.
https://www.msn.com/en-gb/news/coronavirus/exclusive-first-coronavirus-antibody-test-given-approval-by-public-health-england/ar-BB142Udu
Are ‘Boots’ going to recruit ‘professional health workers’ or will they say untrained/non-professionals can carry out any anti-body test. Even though at the moment the standard is that ‘professionals health workers’ have to perform the current market testing. The Roche test is even more intricate as it requires an invasive Venepuncture procedure and will have to be undertaken by those wearing enclosed ‘PPE’? In addition, how competent will the logistics process be? Unfortunately my local Boots appear to have difficulty just organising my bi-monthly prescription!

It is very evident that we still require a ‘reliable/validated POC Home test’. I still fully believe the consortium and ODX are the ‘odds on favourites’ to develop this and therefore obtain the GOLDEN TICKET. However, those who are still dithering and sat on the fence (just hope the spikes are not too sharp) or are feeling discombobulated with the current situation. My suggestion would be ‘DON’T PANIC MR(s) INVESTOR’ and is highlighted by one of my favourite comedies: - https://www.bing.com/videos/search?q=don%27t+panic+dad%27s+army&&view=detail&mid=CD8577F8590E762C3A1CCD8577F8590E762C3A1C&&FORM=VRDGAR&ru=%2Fvideos%2Fsearch%3Fq%3Ddon%2527t%2Bpanic%2Bdad%2527s%2Barmy%26%26FORM%3DVDVVXX

Please show patience, good luck to all and stay well.
YB

Latest Share Chat

Member Info for Yorkshireboy

Posts (Last 30 Days)

Posts (All Time)

Last Post

Member Since

Share Chat Post Distribution over the last 30 days